{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T18:18:08Z","timestamp":1759342688526},"reference-count":61,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","cidjournal.com","clinicalkey.es","theclinics.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Dermatology"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.clindermatol.2016.10.016","type":"journal-article","created":{"date-parts":[[2016,10,27]],"date-time":"2016-10-27T21:15:42Z","timestamp":1477602942000},"page":"207-212","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Pharmacologic treatments for rosacea"],"prefix":"10.1016","volume":"35","author":[{"given":"Alison M.","family":"Layton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clindermatol.2016.10.016_bb0005","first-page":"277","article-title":"Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 2: A status report on topical agents","volume":"92","author":"Del Rosso","year":"2013","journal-title":"Cutis"},{"key":"10.1016\/j.clindermatol.2016.10.016_bb0010","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1111\/j.1468-3083.2010.03751.x","article-title":"Rosacea-global diversity and optimized outcome: Proposed international consensus from the Rosacea International Expert Group","volume":"25","author":"Elewski","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2016.10.016_bb0015","first-page":"38","article-title":"Rosacea: A review","volume":"34","author":"Culp","year":"2009","journal-title":"P T"},{"key":"10.1016\/j.clindermatol.2016.10.016_bb0020","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1111\/j.1468-3083.2009.03167.x","article-title":"Current topical and systemic approaches to treatment of rosacea","volume":"23","author":"Korting","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2016.10.016_bb0025","first-page":"838","article-title":"Optimal Management of papulopustular rosacea: Rationale for combination therapy","volume":"11","author":"Bhatia","year":"2012","journal-title":"J Drug Dermatol"},{"key":"10.1016\/j.clindermatol.2016.10.016_bb0030","first-page":"679","article-title":"Topical metronidazole maintains remissions of rosacea","volume":"134","author":"Dahl","year":"1998","journal-title":"J Drug Dermatol"},{"key":"10.1016\/j.clindermatol.2016.10.016_bb0035","first-page":"639","article-title":"A multicenter study of topical azelaic acid 15% gel in combination with oral doxycycline as initial therapy and azelaic acid 15% gel as maintenance monotherapy","volume":"8","author":"Thiboutot","year":"2009","journal-title":"J Drug Dermatol"},{"key":"10.1016\/j.clindermatol.2016.10.016_bb0040","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/S0190-9622(99)70022-8","article-title":"Treatment of rosacea-like demodicidosis with oral invermectin and topical permethrin cream","volume":"41","author":"Forstinger","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2016.10.016_bb0045","first-page":"27","article-title":"The pharmacological therapy of rosacea; a paradigm shift in progress","volume":"75","author":"Bikowski","year":"2005","journal-title":"Cutis"},{"key":"10.1016\/j.clindermatol.2016.10.016_bb0050","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S0151-9638(05)79308-X","article-title":"Demodecie chez un malade infecte par le VIH: Guerison pas ivermectine","volume":"132","author":"Clyti","year":"2005","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2016.10.016_bb0055","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1111\/j.1365-4632.2006.02924.x","article-title":"Ivermectin treatment of three cases of demodecidosis during human immunodeficiency virus infection","volume":"45","author":"Clyti","year":"2006","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.clindermatol.2016.10.016_bb0060","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1111\/j.1472-8206.2009.00684.x","article-title":"Avermectin exerts anti-inflammatory effect by down regulating the nuclear transcription factor kappa-B and mitogen activated protein kinase activation pathway","volume":"23","author":"Ci","year":"2009","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.clindermatol.2016.10.016_bb0065","first-page":"316","article-title":"Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: Results of two randomized, double-blind, vehicle controlled pivotal studies","volume":"13","author":"Stein-Gold","year":"2014","journal-title":"J Drug Dermatol"},{"key":"10.1016\/j.clindermatol.2016.10.016_bb0070","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1111\/bjd.13408","article-title":"Ivermectin Phase III study group. Superiority of ivermectin 1% cream over metronidazole 0.75% cream in treating inflammatory lesions of rosacea: A randomised, investigator-blinded trial","volume":"172","author":"Taieb","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2016.10.016_bb0075","doi-asserted-by":"publisher","first-page":"S44","DOI":"10.1016\/j.jaad.2013.06.009","article-title":"Management of facial erythema of rosacea: What is the role of topical \u03b1-adrenergic receptor agonist therapy?","volume":"69","author":"Del Rosso","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2016.10.016_bb0080","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1111\/j.1365-2133.2011.10716.x","article-title":"Brimonidine Phase II Study Group. Once-daily topical brimonidine tartrate gel 0\u00b75% is a novel treatment for moderate to severe facial erythema of rosacea: Results of two multicentre, randomized and vehicle-controlled studies","volume":"166","author":"Fowler","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2016.10.016_bb0085","first-page":"650","article-title":"Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: Results of two randomized, double-blind, and vehicle-controlled pivotal studies","volume":"12","author":"Fowler","year":"2013","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.clindermatol.2016.10.016_bb0090","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1517\/14740331003709736","article-title":"Brimonidine for glaucoma","volume":"9","author":"Rahman","year":"2010","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.clindermatol.2016.10.016_bb0095","first-page":"26","article-title":"Advances in understanding and managing rosacea: Part 2","volume":"5","author":"Del Rosso","year":"2012","journal-title":"J Clin Aesthet Dermatol"},{"key":"10.1016\/j.clindermatol.2016.10.016_bb0100","first-page":"449","article-title":"Objective evaluation of the effect of intense pulsed light on rosacea and solar lentigines by spectrophotometric analysis of skin color","volume":"33","author":"Kawana","year":"2007","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.clindermatol.2016.10.016_bb0105","first-page":"71","article-title":"Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 4: A status report on physical modalities and devices","volume":"93","author":"Tanghetti","year":"2014","journal-title":"Cutis"},{"key":"10.1016\/j.clindermatol.2016.10.016_bb0110","first-page":"33","article-title":"Optimising use of topical brimonidine in rosacea management: Panel recommendations","volume":"14","author":"Tanghetti","year":"2015","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.clindermatol.2016.10.016_bb0115","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/j.1365-4632.2004.02130.x","article-title":"Adapalene vs metronidazole gel for the treatment of rosacea","volume":"44","author":"Altinyazar","year":"2005","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.clindermatol.2016.10.016_bb0120","first-page":"1179","article-title":"Efficacy of a novel rosacea treatment system: An investigator-blind, randomized, parallel-group study","volume":"10","author":"Leyden","year":"2011","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.clindermatol.2016.10.016_bb0125","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/ijd.12552","article-title":"Clinical and experimental assessment of the effects of a new topical treatment with praziquantel in the management of rosacea","volume":"54","author":"Bribeche","year":"2015","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.clindermatol.2016.10.016_bb0130","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1038\/jid.2013.472","article-title":"Reduction in serine protease activity correlates with improved rosacea severity in a small, randomized pilot study of a topical serine protease inhibitor","volume":"134","author":"Two","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clindermatol.2016.10.016_bb0135","first-page":"685","article-title":"Randomized, phase 2, dose-ranging study in the treatment of rosacea with encapsulated benzoyl peroxide gel","volume":"13","author":"Leyden","year":"2014","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.clindermatol.2016.10.016_bb0140","first-page":"183","article-title":"The comparative efficacy of sodium sulfacetamide 10%\/sulfur 5% (Sulfacet-R) lotion and metronidazole 0.75% (Metrogel) in the treatment of rosacea","volume":"3","author":"Lebwohl","year":"1995","journal-title":"J Geriatr Dermatol"},{"key":"10.1016\/j.clindermatol.2016.10.016_bb0145","first-page":"333","article-title":"A randomized, double-blind, placebo-controlled, pilot study to assess the efficacy and safety of clindamycin 1.2% and tretinoin 0.025% combination gel for the treatment of acne rosacea over 12 weeks","volume":"11","author":"Chang","year":"2012","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.clindermatol.2016.10.016_bb0150","year":"2014","journal-title":"Novartis"},{"key":"10.1016\/j.clindermatol.2016.10.016_bb0155","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/jdv.12520","article-title":"A multicentre, randomized, placebo-controlled trial establishing the treatment effect of TDT 068, a topical formulation containing drug-free ultra-deformable phospholipid vesicles, on the primary features of erythematotelangiectatic rosacea","volume":"29","author":"Luger","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2016.10.016_bb0160","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1111\/j.1365-2133.2006.07669.x","article-title":"Pimecrolimus cream 1% for papulopustular rosacea: A randomized vehicle-controlled double-blind trial","volume":"156","author":"Weissenbacher","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2016.10.016_bb0165","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003262.pub5","article-title":"Interventions for Rosacea","volume":"4","author":"van Zuuren","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clindermatol.2016.10.016_bb0170","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2165\/11530200-000000000-00000","article-title":"The role of tetracyclines in rosacea","volume":"11","author":"Alikhan","year":"2010","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.clindermatol.2016.10.016_bb0175","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1111\/j.1468-3083.2009.03132.x","article-title":"Ocular signs, symptoms and tear function tests of papulopustular rosacea patients receiving azithromycin","volume":"23","author":"Bakar","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2016.10.016_bb0180","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1111\/j.1540-9740.2003.03014.x","article-title":"Sub-antimicrobial dose doxycycline for acne and rosacea","volume":"2","author":"Bikowski","year":"2003","journal-title":"Skinmed"},{"key":"10.1016\/j.clindermatol.2016.10.016_bb0185","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1517\/14740338.7.5.571","article-title":"The use and safety of doxycycline hyclate and other second-generation tetracyclines","volume":"7","author":"Sloan","year":"2008","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.clindermatol.2016.10.016_bb0190","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1001\/archderm.1994.01690030091015","article-title":"Rosacea pathophysiology and treatment","volume":"130","author":"Wilkin","year":"1994","journal-title":"J Drug Dermatol"},{"key":"10.1016\/j.clindermatol.2016.10.016_bb0195","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.jaad.2009.01.019","article-title":"New insights into the management of acne: An update from the Global Alliance to Improve Outcomes in Acne group","volume":"60","author":"Thiboutot","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2016.10.016_bb0200","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1177\/08959374980120012001","article-title":"The potential role of doxycycline in the treatment of osteoarthritis of the temporomandibular joint","volume":"12","author":"Israel","year":"1998","journal-title":"Adv Dent Res"},{"key":"10.1016\/j.clindermatol.2016.10.016_bb0205","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.jaad.2006.11.021","article-title":"Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea","volume":"56","author":"Del Rosso","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2016.10.016_bb0210","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1902\/jop.2008.080051","article-title":"Doxycycline reduces lipopolysaccharide-induced inflammatory mediator secretion in macrophage and ex vivo human whole blood models","volume":"79","author":"Cazalis","year":"2008","journal-title":"J Periodontol"},{"key":"10.1016\/j.clindermatol.2016.10.016_bb0215","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/0266-4356(94)90137-6","article-title":"Effects of antibiotics on human polymorphonuclear leukocyte chemotaxis in vitro","volume":"32","author":"Ueyama","year":"1994","journal-title":"Br J Oral Maxillofac Surg"},{"key":"10.1016\/j.clindermatol.2016.10.016_bb0220","first-page":"1807","article-title":"Chemically modified non-antimicrobial tetracyclines inhibit activity of phospholipases A2","volume":"25","author":"Pruzanski","year":"1998","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clindermatol.2016.10.016_bb0225","doi-asserted-by":"publisher","first-page":"567","DOI":"10.4049\/jimmunol.176.1.567","article-title":"Doxycycline modulates nitric oxide production in murine lung epithelial cells","volume":"176","author":"Hoyt","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.clindermatol.2016.10.016_bb0230","doi-asserted-by":"crossref","first-page":"178","DOI":"10.2340\/0001555572178179","article-title":"Effect of doxycycline on the generation of reactive oxygen species: A possible mechanism of action of acne therapy with doxycycline","volume":"72","author":"Akamatsu","year":"1992","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.clindermatol.2016.10.016_bb0235","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1080\/02713680802245772","article-title":"Inhibitory effect of oral doxycycline on neovascularization in a rat corneal alkali burn model of angiogenesis","volume":"33","author":"Dan","year":"2008","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.clindermatol.2016.10.016_bb0240","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1038\/jid.2012.14","article-title":"Doxycycline indirectly inhibits proteolytic activation of tryptic kallikrein-related peptidases and activation of cathelicidin","volume":"132","author":"Kanada","year":"2012","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clindermatol.2016.10.016_bb0245","first-page":"573","article-title":"Comparison of anti-inflammatory dose doxycycline versus doxycycline 100 mg in the treatment of rosacea","volume":"7","author":"Del Rosso","year":"2008","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.clindermatol.2016.10.016_bb0250","first-page":"7","article-title":"An open label, community based, 12 week assessment of the effectiveness and safety of monotherapy with doxycycline 40 mg (30 mg immediate release and 10 mg delayed release beads)","volume":"86","author":"Webster","year":"2010","journal-title":"Cutis"},{"key":"10.1016\/j.clindermatol.2016.10.016_bb0255","first-page":"505","article-title":"Systemic isotretinoin in the treatment of rosacea-doxycycline- and placebo-controlled, randomized clinical study","volume":"8","author":"Gollnick","year":"2010","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.clindermatol.2016.10.016_bb0260","first-page":"22","article-title":"Updated physician's guide to the off-label uses of oral isotretinoin","volume":"7","author":"Nickle","year":"2014","journal-title":"J Clin Aesthet Dermatol"},{"key":"10.1016\/j.clindermatol.2016.10.016_bb0265","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/S0190-9622(86)70248-X","article-title":"Retinoid effects on fibroblast proliferation and collagen synthesis in vitro and on fibrotic cells in vivo","volume":"15","author":"Daly","year":"1986","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2016.10.016_bb0270","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1111\/j.1365-2133.2009.09317.x","article-title":"Carbon dioxide laser treatment of rhinophyma: A review of 124 patients","volume":"161","author":"Madan","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2016.10.016_bb0275","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.jaad.2005.07.021","article-title":"Symptomatic treatment of idiopathic and rosacea-associated cutaneous flushing with propranolol","volume":"53","author":"Craige","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2016.10.016_bb0280","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.jaad.2012.04.017","article-title":"Pronounced facial flushing and persistent erythema of rosacea effectively treated by carvedilol, a nonselective beta-adrenergic blocker","volume":"67","author":"Hsu","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2016.10.016_bb0285","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1001\/archdermatol.2011.204","article-title":"Carvedilol for the treatment of refractory facial flushing and persistent erythema of rosacea","volume":"147","author":"Hsu","year":"2011","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2016.10.016_bb0290","first-page":"149","article-title":"Recalcitrant papulopustular rosacea in an immunocompetent patient responding to combination therapy with oral ivermectin and topical permethrin","volume":"80","author":"Allen","year":"2007","journal-title":"Cutis"},{"key":"10.1016\/j.clindermatol.2016.10.016_bb0295","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1159\/000066430","article-title":"Ivermectin-responsive Demodex infestation during human immunodeficiency virus infection. A case report and literature review","volume":"205","author":"Aquilina","year":"2002","journal-title":"Dermatology"},{"key":"10.1016\/j.clindermatol.2016.10.016_bb0300","first-page":"292","article-title":"Efficacy of extended-release 45 mg oral minocycline and extended-release 45 mg oral minocycline plus 15% azelaic acid in the treatment of acne rosacea","volume":"12","author":"Jackson","year":"2013","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.clindermatol.2016.10.016_bb0305","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/j.1365-4632.2011.05353.x","article-title":"Randomized, double-blind trial of 220 mg zinc sulfate twice daily in the treatment of rosacea","volume":"51","author":"Bamford","year":"2012","journal-title":"Int J Dermatol"}],"container-title":["Clinics in Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X16302772?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X16302772?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T17:18:21Z","timestamp":1692551901000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0738081X16302772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":61,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S0738081X16302772"],"URL":"https:\/\/doi.org\/10.1016\/j.clindermatol.2016.10.016","relation":{},"ISSN":["0738-081X"],"issn-type":[{"value":"0738-081X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacologic treatments for rosacea","name":"articletitle","label":"Article Title"},{"value":"Clinics in Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clindermatol.2016.10.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2016 Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}